Summary
Global Markets Direct’s, ‘Thrombocytopenia - Pipeline Review, H1 2016’, provides an overview of the Thrombocytopenia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia
- The report reviews pipeline therapeutics for Thrombocytopenia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thrombocytopenia therapeutics and enlists all their major and minor projects
- The report assesses Thrombocytopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thrombocytopenia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
3SBio Inc.
Amarillo Biosciences, Inc.
Amgen Inc.
Baxalta Incorporated
Bayer AG
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Cellerant Therapeutics, Inc.
Eisai Co., Ltd.
Genosco
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Myelo Therapeutics GmbH
Neumedicines Inc.
Novartis AG
Pfizer Inc.
PhytoHealth Corporation
Prophylix Pharma AS
Protalex, Inc.
Rigel Pharmaceuticals, Inc.
Shionogi & Co., Ltd.
STATegics, Inc.
UCB S.A.
ViroMed Co., Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Thrombocytopenia Overview 11
Therapeutics Development 12
Pipeline Products for Thrombocytopenia - Overview 12
Pipeline Products for Thrombocytopenia - Comparative Analysis 13
Thrombocytopenia - Therapeutics under Development by Companies 14
Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes 16
Thrombocytopenia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Thrombocytopenia - Products under Development by Companies 20
Thrombocytopenia - Products under Investigation by Universities/Institutes 23
Thrombocytopenia - Companies Involved in Therapeutics Development 24
3SBio Inc. 24
Amarillo Biosciences, Inc. 25
Amgen Inc. 26
Baxalta Incorporated 27
Bayer AG 28
BioLineRx, Ltd. 29
Boehringer Ingelheim GmbH 30
Bolder Biotechnology, Inc. 31
Bristol-Myers Squibb Company 32
Cellerant Therapeutics, Inc. 33
Eisai Co., Ltd. 34
Genosco 35
Hansa Medical AB 36
Immunomedics, Inc. 37
Intas Pharmaceuticals Ltd. 38
Jiangsu Hengrui Medicine Co., Ltd. 39
Merck & Co., Inc. 40
Momenta Pharmaceuticals, Inc. 41
Myelo Therapeutics GmbH 42
Neumedicines Inc. 43
Novartis AG 44
Pfizer Inc. 45
PhytoHealth Corporation 46
Prophylix Pharma AS 47
Protalex, Inc. 48
Rigel Pharmaceuticals, Inc. 49
Shionogi & Co., Ltd. 50
STATegics, Inc. 51
UCB S.A. 52
ViroMed Co., Ltd. 53
Thrombocytopenia - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
avatrombopag - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BBT-059 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BI-655064 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
BL-8040 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
BMS-986004 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CLT-009 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
eltrombopag olamine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
eltrombopag olamine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
fostamatinib disodium - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
GL-2045 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
GSK-2285921 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Hetrombopag Olamine - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
interferon alfa - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
lusutrombopag - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
MK-8723 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Monoclonal Antibody to Agonize TpoR for Thrombocytopenia - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Myelo-001 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
NMIL-121 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
PBF-1509 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
PEG-VM501 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
PHN-013 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
PRTX-100 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
rivaroxaban - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
romiplostim - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
romiplostim biosimilar - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
SKIO-703 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
SM-101 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
STST-4 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
thrombopoietin - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Tromplate - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
TXA-302 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
UCB-7665 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
veltuzumab - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Thrombocytopenia - Recent Pipeline Updates 129
Thrombocytopenia - Dormant Projects 165
Thrombocytopenia - Discontinued Products 168
Thrombocytopenia - Product Development Milestones 169
Featured News & Press Releases 169
Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia 169
Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP 170
Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 171
Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag 172
Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 172
Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 173
Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia 174
Sep 28, 2015: Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia 174
Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 175
Sep 04, 2015: Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 175
Appendix 177
Methodology 177
Coverage 177
Secondary Research 177
Primary Research 177
Expert Panel Validation 177
Contact Us 177
Disclaimer 178
List of Tables
Number of Products under Development for Thrombocytopenia, H1 2016 12
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Development by Companies, H1 2016 (Contd..2) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Thrombocytopenia - Pipeline by 3SBio Inc., H1 2016 24
Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H1 2016 25
Thrombocytopenia - Pipeline by Amgen Inc., H1 2016 26
Thrombocytopenia - Pipeline by Baxalta Incorporated, H1 2016 27
Thrombocytopenia - Pipeline by Bayer AG, H1 2016 28
Thrombocytopenia - Pipeline by BioLineRx, Ltd., H1 2016 29
Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H1 2016 30
Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H1 2016 31
Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H1 2016 32
Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016 33
Thrombocytopenia - Pipeline by Eisai Co., Ltd., H1 2016 34
Thrombocytopenia - Pipeline by Genosco, H1 2016 35
Thrombocytopenia - Pipeline by Hansa Medical AB, H1 2016 36
Thrombocytopenia - Pipeline by Immunomedics, Inc., H1 2016 37
Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H1 2016 38
Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 39
Thrombocytopenia - Pipeline by Merck & Co., Inc., H1 2016 40
Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 41
Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H1 2016 42
Thrombocytopenia - Pipeline by Neumedicines Inc., H1 2016 43
Thrombocytopenia - Pipeline by Novartis AG, H1 2016 44
Thrombocytopenia - Pipeline by Pfizer Inc., H1 2016 45
Thrombocytopenia - Pipeline by PhytoHealth Corporation, H1 2016 46
Thrombocytopenia - Pipeline by Prophylix Pharma AS, H1 2016 47
Thrombocytopenia - Pipeline by Protalex, Inc., H1 2016 48
Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 49
Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H1 2016 50
Thrombocytopenia - Pipeline by STATegics, Inc., H1 2016 51
Thrombocytopenia - Pipeline by UCB S.A., H1 2016 52
Thrombocytopenia - Pipeline by ViroMed Co., Ltd., H1 2016 53
Assessment by Monotherapy Products, H1 2016 54
Number of Products by Stage and Target, H1 2016 56
Number of Products by Stage and Mechanism of Action, H1 2016 59
Number of Products by Stage and Route of Administration, H1 2016 62
Number of Products by Stage and Molecule Type, H1 2016 64
Thrombocytopenia Therapeutics - Recent Pipeline Updates, H1 2016 129
Thrombocytopenia - Dormant Projects, H1 2016 165
Thrombocytopenia - Dormant Projects (Contd..1), H1 2016 166
Thrombocytopenia - Dormant Projects (Contd..2), H1 2016 167
Thrombocytopenia - Discontinued Products, H1 2016 168
List of Figures
Number of Products under Development for Thrombocytopenia, H1 2016 12
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 54
Number of Products by Top 10 Targets, H1 2016 55
Number of Products by Stage and Top 10 Targets, H1 2016 55
Number of Products by Top 10 Mechanism of Actions, H1 2016 58
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 58
Number of Products by Routes of Administration, H1 2016 61
Number of Products by Stage and Routes of Administration, H1 2016 61
Number of Products by Top 10 Molecule Types, H1 2016 63
Number of Products by Stage and Top 10 Molecule Types, H1 2016 63
